abstract the present invention relates to novel 4-pregenen-11ß-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation. __________________________ translation of abstract summary patent: "pregenen-11ss-17-21-triol-3,20-dione derivatives for the treatment of eye conditions". The present invention relates to novel derivatives of 4-pregenen-11-17-21-triol-3,20-dione, process for their preparation, pharmaceutical compositions containing them and their use as pharmaceutical agents, as modulators of receptor for glucocorticoid or mineralocorticoid. The invention specifically relates to the use of such compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.abstract the present invention relates to novel 4-pregenen-11ß-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. the invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation. __________________________ tradução do resumo resumo patente de invenção: "derivados de pregenen-11ss-17-21-triol-3,20-diona para o tratamento de condições oculares". a presente invenção refere-se a novos derivados de 4-pregenen-11-17-21-triol-3,20-diona, processo para sua preparação, composições farmacêuticas contendo-os e seu uso como agentes farmacêuticos, como moduladores de receptores de glucocorticoide ou mineralocorticoide. a invenção
